Martha Hernandez‐Illas

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

Michael J. Koren, Patrick M. Moriarty, Seth J. Baum et al. · Nature Medicine · 2022 · 218 citations

Translational Medicine, Preclinical Development, Medicine +6

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

Shweta Urva, Tamer Coşkun, Mei Teng Loh et al. · The Lancet · 2022 · 180 citations

Glucagon Receptor Agonist, G Protein-coupled Receptor, Medicine +6

Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults

Xiang‐Qing Yu, Gabriel J. Robbie, Yuling Wu et al. · Antimicrobial Agents and Chemotherapy · 2016 · 134 citations · Full text

Therapeutic Drug Monitoring, Antimicrobial Susceptibility, Serum Half-life +15

Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults

Omar Ali, Xiang‐Qing Yu, Gabriel J. Robbie et al. · Clinical Microbiology and Infection · 2018 · 123 citations · Full text

Pharmacokinetics and pharmacodynamics of PF‐05231023, a novel long‐acting FGF21 mimetic, in a first‐in‐human study

Jennifer Dong, Michelle I. Rossulek, Veena Somayaji et al. · British Journal of Clinical Pharmacology · 2015 · 98 citations · Full text